In vertebrate animals, the heart is a hollow muscular organ having four pumping chambers: the left atrium, the left ventricle, the right atrium and the right ventricle. The atria are isolated from their respective ventricles by one-way valves located at the respective atrial-ventricular junctions. These valves are identified as the mitral (or bicuspid) valve on the left side of the heart, and tricuspid valve on the right side of the heart. The exit valves from the left and right ventricles are identified as the aortic and pulmonary valves, respectively.
The valves of the heart are positioned in valvular annuluses that comprise dense fibrous rings attached either directly or indirectly to the atrial and ventricular muscle fibers. Valve leaflets comprising flexible collagenous structures are attached to, and extend inwardly from, the annuluses to meet at coapting edges. The aortic, tricuspid and pulmonary valves each have three leaflets, while the mitral valve only has two. In normal operation, the leaflets of the mitral valve open as left ventricle dilates thereby permitting blood to flow from the left atrium into the left ventricle. The leaflets then coapt (i.e. close) during the contraction cycle of the left ventricle, thereby preventing the blood from returning to the left atrium and forcing the blood to exit the left ventricle through the aortic valve. Similarly, the tricuspid valve regulates flow from the right atrium into the right ventricle, and the pulmonary valve regulates blood exiting the right ventricle.
For a number of clinical reasons various problems with heart valves can develop. One common form of heart disease involves the deterioration or degradation of the heart valves, which leads to stenosis and/or insufficiency. Heart valve stenosis is a condition in which the valve does not open properly. Insufficiency is a condition in which the valve does not close properly. Insufficiency of the mitral valve, most common because of the relatively high fluid pressures in the left ventricle, results in mitral valve regurgitation (“MR”), a condition in which blood reverses its intended course and flows “backward” from the left ventricle to the left atrium during heart contractions.
A number of surgical techniques have been developed to repair degraded or otherwise incompetent heart valves. A common procedure involves replacement of a native aortic or mitral valve with a prosthetic heart valve. Such procedures require the surgeon to access the heart through the patient's chest (or possibly percutaneously), surgically remove the incompetent native heart valve and associated tissue, remodel the surrounding valve annulus, and secure a replacement valve in the remodeled annulus. While these procedures can be very effective, there are associated shortcomings. For example, the highly invasive nature of the implantation procedure typically results in substantial patient discomfort and requires patients to remain hospitalized for extended recovery periods. In addition, the two basic types of commercially available replacement valves, mechanical valves, and tissue valves, have shortcomings of their own. Mechanical replacement valves typically offer extended operational lifetimes, but the patient is usually required to maintain a regimen of anti-coagulant drugs for the remainder of his or her life. Tissue valves typically offer a higher degree of acceptance by the body thereby reducing or eliminating the need for anti-coagulants, but the operational lifetimes of tissue valves is typically shorter than mechanical valves and thus may require a subsequent replacement(s).
As an alternative to prosthetic heart valve replacement, it is often preferable to remodel the native heart valve and/or surrounding tissue. Remodeling procedures often preserve left ventricular function better than mitral valve replacement because the subvalvular papillary muscles and chordae tendineae are preserved (most prosthetic valves do not utilize these muscles). Typically, valvular remodeling is accomplished by implanting a prosthetic ring (“annuloplasty ring”) into the valve annulus to reduce and/or stabilize the structure of the annulus. Annuloplasty rings are typically constructed of a resilient core covered with a fabric sewing material. Annuloplasty procedures can be performed alone, or they can be performed in conjunction with other procedures such as leaflet repair. Although annuloplasty procedures have become popular and well accepted, reshaping the surrounding annulus and traditional leaflet repairs do not always lead to optimum leaflet coaptation. As a result, some patients may still experience residual mitral valve regurgitation following annuloplasty procedures.
A recently developed technique known as a “bow-tie” repair has also been advocated for repairing insufficient heart valves, in particular the mitral valve. The mitral valve bow-tie technique involves, in its simplest form, suturing the anterior and posterior leaflets together near the middle of their coapting edges, thereby causing blood to flow through two newly formed side openings. While this does reduce the volume of blood that flows from the atrium to the ventricle, this loss is more than compensated by improved leaflet coaptation, which reduces mitral regurgitation. As originally developed by Dr. Ottavio Alfieri, this process involved arresting the heart, and placing the patient on extra corporeal bypass and required invasive surgery to access and suture the leaflets together. More recently, however, some have advocated a “beating heart” procedure in which the leaflets are accessed remotely and the heart remains active throughout the procedure.
A particular method for performing a beating heart bow-tie procedure (i.e. without extra corporeal bypass) has been proposed by Dr. Mehmet Oz, of Columbia University. The method and devices for performing the method are described in PCT publication WO 99/00059, published Jan. 7, 1999. In one embodiment of the disclosed procedure, the associated device consists of a forceps-like grasper used to grasp and hold the mitral valve leaflets in a coapted position for suturing. Since the mitral valve leaflets meet and curve toward and slightly into the left ventricular cavity at their mating edges, the grasper device is passed through a sealed aperture in the apex of the left ventricle. The edges of the mating mitral valve leaflets are then grasped and held together, and a fastening device such as a clip or suture is utilized to fasten them. The fastening device should be applied to the leaflet tissue with sufficient tissue purchase to prevent tear out or other failure, but close enough to the edges to ensure that the newly created side holes are as large as possible. The Mehmet Oz disclosure thus illustrates that teeth of the grasper device can be linearly slidable with respect to one another so as to permit alignment of the mitral valve leaflets prior to fastening. Since the procedure is done on a beating heart, it will be readily understood that the pressures and motions within the left ventricle and mitral valve leaflets are severe. Thus the procedure taught by Dr. Mehmet Oz is very skill-intensive.
The bow-tie technique has proved to be a viable alternative for treating otherwise incompetent heart valves. Nonetheless, several shortcomings associated with current bow-tie procedures have been identified. Current systems include devices having mechanical graspers, barbed members, and vacuum devices that simultaneously capture and retain the valve leaflets prior to applying a fastening device thereto. Often, use of these devices results in the less than optimal leaflet stabilization and fastener placement. Many of these problems arise from the fact that the surgeon is required to capture, retain and fasten the leaflets in one relatively inflexible procedure. These difficulties are compounded when the leaflets are small or calcified making them difficult to pull together, and in beating heart procedures in which the leaflets are actively functioning throughout the surgery. In light of the foregoing, there is presently a need for improved systems for stabilizing multiple tissue heart valve leaflets and placing a fastening device there between. More specifically, there is a present need for an improved bow-tie procedure for repairing a patient's mitral valve.
The single catheter mitral valve repair device of the present invention may be used to repair tissue throughout a patient's body. However, it is particularly useful in repairing dysfunctional mitral valve tissue by stabilizing discreet valvular tissue pieces and deploying a fastening device therethrough, thereby coapting the tissue pieces. The present invention may also be used to repair arterial septal defects (ASD), ventricular septal defects (VSD), and defects associated with patent foramen ovale (PFO).
In one aspect, the repair device of the present invention comprises an extendable engagement tip having at least one port formed thereon, at least one deployable fastener in communication with the engagement tip, and one or more actuator members in communication with the port(s). The deployable fastener is capable of controllably engaging and fastening tissue located proximal to the engagement tip.
In another aspect of the present invention, the repair device comprises a handle, an elongated body, and an extendable engagement tip. The handle comprises a stationary handle body, an engagement tip actuator in communication with the stationary handle body, a fastener deployment housing in communication with the stationary handle body, and a vacuum connector capable of placing a vacuum source in communication with the stationary handle body. The elongated body comprises a flexible body member, at least one vacuum lumen, one or more actuation lumens and one or more fastener lumens. Optionally, the elongated body can also comprise one or more auxiliary lumens. The one or more actuation lumens are capable of receiving one or more actuation members therein. Similarly, the one or more fastener lumens are capable of receiving at least one deployable fastener therein. The extendable engagement tip comprises a fastener deployment housing capable of attaching to the elongated body, an actuation flange attached to the fastener deployment housing, an extendable tip attached to the actuation flange and in communication with the engagement tip actuator, a vacuum port in communication with the vacuum connector, and at least one deployable fastener in communication with the fastener deployment housing.
The present invention also discloses a method of repairing tissue using the repair device of the present invention and comprises grasping a first tissue portion with a vacuum force, stabilizing the first tissue portion with a mechanical force, deploying a tissue fastener into the stabilized first tissue portion, disengaging the first tissue portion, grasping at least a second tissue portion with a vacuum force, stabilizing at least a second tissue portion with a mechanical force, deploying at least a second tissue fastener into at least the second stabilized tissue portion, disengaging at least the second tissue portion, and coapting the first tissue portion and at least the second tissue portion with the first tissue fastener and at least the second tissue fastener.
Other objects, features, and advantages of the present invention will become apparent from a consideration of the following detailed description.
The apparatus of the present invention will be explained in more detail by way of the accompanying drawings, wherein:
Disclosed herein is a detailed description of various embodiments of the present invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of illustrating the general principles of the invention. The overall organization of the description is for the purpose of clarity only and is not intended to limit the present invention.
The single catheter mitral valve repair device of the present invention is designed for use in a surgical treatment of bodily tissue. As those skilled in the art will appreciate, the exemplary single catheter mitral repair device disclosed herein is designed to minimize trauma to the patient before, during, and after a minimally invasive surgical procedure while providing improved tissue stabilization and enhanced placement of a fastening device thereon. While the single catheter mitral valve repair device of the present invention may be used to repair tissue throughout a patient's body, it is particularly useful in repairing dysfunctional mitral valve tissue by stabilizing discreet valvular tissue pieces and deploying a fastening device therethrough, thereby coapting the tissue pieces. The present invention may also be used to repair arterial septal defects (ASD), ventricular septal defects (VSD), and defects associated with patent foramen ovale (PFO).
The elongated body 14 of the present invention may be manufactured in a variety of lengths or diameters as desired by the user.
The present invention also discloses a method of using the single catheter mitral valve repair device of the present invention to repair discreet tissue portions in vivo. The description below describes a method of repairing dysfunctional heart valves, however, those skilled in the art will appreciate that the present invention may be adapted for use in other tissue repair procedures.
To repair a dysfunctional or otherwise incompetent heart valve, a guidewire capable of traversing the circulatory system and entering the heart of the patient is introduced into the patient through an endoluminal entry point. For example, an endoluminal entry point may be formed in a femoral vein or right jugular vein of a patient. Thereafter, the guidewire may be introduced into the patient through the endoluminal entry point and advanced through the circulatory system, eventually arriving at the heart. Upon arriving at the heart, the guidewire is directed into the right atrium of the heart, traverses the right atrium and is made to puncture the atrial septum, thereby entering the left atrium. The guidewire may then be advanced through the mitral valve while the heart is in diastole and traverses the left ventricle. The guidewire traverses the aortic valve into the aorta and is made to emerge from the left femoral artery through an endoluminal exit point. This methodology of positioning a guidewire is known to physicians skilled in the art of interventional cardiology. Once the guidewire is positioned, the endoluminal entry or exit port is dilated to permit entry of a catheter therethrough. A protective sheath may be advanced in the venous area to protect the vascular structure.
With the guidewire suitably anchored, the distal portion of the mitral valve repair device of the present invention may be attached to the guidewire. Thereafter, the elongated body 14 having the engagement tip 16 attached thereto is advanced through the dilated guidewire entry port to a point proximate the cusp portion of the mitral valve. Those skilled in the art will appreciate that the mitral valve repair device 10 of the present invention may approach the cusp of the mitral valve from an antegrade position or from a retrograde position as desired by the user. For a retrograde approach, the user attaches the repair device 10 to the guidewire emerging from the left femoral artery. The device is then advanced along the guidewire to a position proximate the retrograde aspect of the mitral valve. The engagement tip 16 of the mitral valve repair device 10 may be positioned proximate the tissue portion 72 of the mitral valve. Once suitably positioned, the tip actuator 22 positioned on the handle 12 may be actuated, thereby resulting in the extendable tip 48 of the engagement tip 16 extending distally from the fastener deployment housing 46. Thereafter, an external vacuum source (not shown) may be activated to apply a vacuum force to the mitral valve repair device 10 through the vacuum connector 18. The external vacuum source (not shown) communicates with the vacuum port 52 located on the engagement tip 16 through the at least one vacuum lumen 36 in the elongated body 14. With the extendable tip 48 distally extended from the fastener deployment housing 46, the tissue portion 72 located proximate to the vacuum port 52 is grasped and retained by the vacuum force applied by the external vacuum source (not shown). Once the tissue portion 72 is captured by the vacuum force supplied through the vacuum port 52, the tip actuator 22 located on the handle 12 is actuated to retract the extendable tip 48 toward the fastener deployment housing 46 thereby mechanically retaining and stabilizing the tissue portion 72 therebetween. Once the tissue is sufficiently stabilized, the fastener deployment actuator 24 located on the handle 12 may be actuated to deploy a fastening device through the tissue portion 72. To deploy the fastener device the user advances the fastener deployment actuator 24 toward the handle flange 28 positioned on the stationary handle body 20 of the handle 12, thereby causing the deployable needle 64 to exit the deployment port 56 and traverse the tissue positioned within the actuation flange 50. Thereafter, the deployable needle 64 enters the receiver port 58 formed on the extendable tip 48 and engages the needle catch 68 which is attached to the fastener material 62 positioned within the fastener channel 60. The fastener deployment housing 46 is returned to a non-deployed position by the user, thereby resulting in the deployable needle 64, which has retained the needle catch 68 attached to the fastener material 60, returning to a non-deployed position within the fastener lumen 44 of the elongated body 14, and resulting in the tissue portion 72 having fastener material 62 positioned therethrough. As shown in
Once removed from the body of the patient, the mitral valve repair device 10 may be reloaded with deployable need and fastener material, rotated, and reintroduced into the patient thereby permitting the device to apply additional tissue fasteners to bodily tissue adjacent that already fastened. At least the distal portion of the mitral valve repair device of the present invention is re-attached to the guidewire. Thereafter, the elongated body 14 having the engagement tip 16 attached thereto is again advanced through the dilated guidewire entry port to a point proximate the cusp portion of the mitral valve. The engagement tip 16 of the mitral valve repair device 10 may be positioned proximate to another tissue portion 74 of the mitral valve. The preceding process is then repeated to secure suture material 62′ to tissue portion 74.
In the alternative embodiments of
In closing, it is understood that the embodiments of the invention disclosed herein are illustrative of the principals of the invention. Other modifications may be employed which are within the scope of the present invention. Accordingly, the present invention is not limited to that precisely as shown and described in the present disclosure.
This application is a continuation of U.S. patent application Ser. No. 13/932,939, filed Jul. 1, 2013, entitled “Single Catheter Mitral Valve Repair Device and Method for Use,” now U.S. Pat. No. 9,314,242, which is a continuation of U.S. patent application Ser. No. 13/584,476, filed Aug. 13, 2012, entitled “Single Catheter Mitral Valve Repair Device and Method for Use,” now U.S. Pat. No. 8,475,472, which is a continuation of U.S. patent application Ser. No. 13/027,045, filed Feb. 14, 2011, entitled “Single Catheter Mitral Valve Repair Device and Method for Use,” now U.S. Pat. No. 8,241,304, which is a continuation of U.S. patent application Ser. No. 11/450,602, filed Jun. 9, 2006, entitled “Single Catheter Mitral Valve Repair Device and Method for Use,” now U.S. Pat. No. 7,887,552, which is a continuation of U.S. patent application Ser. No. 10/233,879, filed Sep. 3, 2002, entitled “Single Catheter Mitral Valve Repair Device and Method for Use,” now U.S. Pat. No. 7,083,628. This application discloses subject matter related to U.S. patent application Ser. No. 09/562,406, filed May 1, 2000, entitled “Minimally Invasive Mitral Valve Repair Method and Apparatus,” now U.S. Pat. No. 6,626,930. The disclosures of all of the aforementioned United States patent applications are expressly incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3769980 | Karman | Nov 1973 | A |
3805793 | Wright | Apr 1974 | A |
4055167 | Bernstein | Oct 1977 | A |
4311140 | Bridgman | Jan 1982 | A |
4350160 | Kolesov et al. | Sep 1982 | A |
5059201 | Asnis | Oct 1991 | A |
5080663 | Mills et al. | Jan 1992 | A |
5242456 | Nash et al. | Sep 1993 | A |
5267958 | Buchbinder et al. | Dec 1993 | A |
5330442 | Green et al. | Jul 1994 | A |
5374275 | Bradley et al. | Dec 1994 | A |
5403326 | Harrison et al. | Apr 1995 | A |
5443446 | Shturman | Aug 1995 | A |
5458131 | Wilk | Oct 1995 | A |
5474573 | Hatcher | Dec 1995 | A |
5540704 | Gordon et al. | Jul 1996 | A |
5549617 | Green | Aug 1996 | A |
5569274 | Rapacki et al. | Oct 1996 | A |
5573540 | Yoon | Nov 1996 | A |
5575800 | Gordon | Nov 1996 | A |
5578044 | Gordon et al. | Nov 1996 | A |
5601574 | Stefanchik et al. | Feb 1997 | A |
5609598 | Laufer et al. | Mar 1997 | A |
5643289 | Sauer et al. | Jul 1997 | A |
5662664 | Gordon et al. | Sep 1997 | A |
5685867 | Twardowski et al. | Nov 1997 | A |
5695457 | St. Goar et al. | Dec 1997 | A |
5695504 | Gifford et al. | Dec 1997 | A |
5700272 | Gordon et al. | Dec 1997 | A |
5713910 | Gordon et al. | Feb 1998 | A |
5713911 | Racenet et al. | Feb 1998 | A |
5716367 | Koike et al. | Feb 1998 | A |
5741277 | Gordon et al. | Apr 1998 | A |
5741279 | Gordon et al. | Apr 1998 | A |
5766183 | Sauer | Jun 1998 | A |
5769863 | Garrison | Jun 1998 | A |
5792094 | Stevens et al. | Aug 1998 | A |
5792153 | Swain et al. | Aug 1998 | A |
5810847 | Laufer et al. | Sep 1998 | A |
5814097 | Sterman et al. | Sep 1998 | A |
5836956 | Buelna et al. | Nov 1998 | A |
5839639 | Sauer et al. | Nov 1998 | A |
5840030 | Ferek-Petric et al. | Nov 1998 | A |
5849019 | Yoon | Dec 1998 | A |
5860992 | Daniel et al. | Jan 1999 | A |
5885238 | Slovens et al. | Mar 1999 | A |
5891159 | Sherman et al. | Apr 1999 | A |
5891160 | Williamson, IV et al. | Apr 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5928224 | Laufer | Jul 1999 | A |
5928250 | Koike et al. | Jul 1999 | A |
5957937 | Yoon | Sep 1999 | A |
5968059 | Ellis et al. | Oct 1999 | A |
5972020 | Carpentier et al. | Oct 1999 | A |
5976159 | Bolduc et al. | Nov 1999 | A |
6004310 | Bardsley et al. | Dec 1999 | A |
6010531 | Donlon et al. | Jan 2000 | A |
6015417 | Reynolds, Jr. | Jan 2000 | A |
6015427 | Mueller et al. | Jan 2000 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6047700 | Eggers et al. | Apr 2000 | A |
6056760 | Koike et al. | May 2000 | A |
6080182 | Shaw et al. | Jun 2000 | A |
6083219 | Laufer | Jul 2000 | A |
6088889 | Luther et al. | Jul 2000 | A |
6117159 | Huebsch et al. | Sep 2000 | A |
6136010 | Modesitt et al. | Oct 2000 | A |
6149660 | Laufer et al. | Nov 2000 | A |
6157852 | Salmon et al. | Dec 2000 | A |
6162233 | Williamson, IV et al. | Dec 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6165204 | Levinson et al. | Dec 2000 | A |
6190357 | Ferrari et al. | Feb 2001 | B1 |
6210419 | Mayenberger et al. | Apr 2001 | B1 |
6234995 | Peacock, III | May 2001 | B1 |
6238336 | Ouchi | May 2001 | B1 |
6269819 | Oz et al. | Aug 2001 | B1 |
6312447 | Grimes | Nov 2001 | B1 |
6443922 | Roberts et al. | Sep 2002 | B1 |
6461366 | Seguin | Oct 2002 | B1 |
6464707 | Bjerken | Oct 2002 | B1 |
6508777 | Macoviak et al. | Jan 2003 | B1 |
6551330 | Bain et al. | Apr 2003 | B1 |
6575971 | Hauck et al. | Jun 2003 | B2 |
6582388 | Coleman et al. | Jun 2003 | B1 |
6626930 | Allen et al. | Sep 2003 | B1 |
6629534 | St. Goar et al. | Oct 2003 | B1 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641592 | Sauer et al. | Nov 2003 | B1 |
6645205 | Ginn | Nov 2003 | B2 |
6752813 | Goldfarb et al. | Jun 2004 | B2 |
6770083 | Seguin | Aug 2004 | B2 |
6860890 | Bachman et al. | Mar 2005 | B2 |
6875224 | Grimes | Apr 2005 | B2 |
6911034 | Nobles et al. | Jun 2005 | B2 |
6997931 | Sauer et al. | Feb 2006 | B2 |
7063710 | Takamoto | Jun 2006 | B2 |
7083628 | Bachman | Aug 2006 | B2 |
7094244 | Schreck | Aug 2006 | B2 |
7887552 | Bachman | Feb 2011 | B2 |
8241304 | Bachman | Aug 2012 | B2 |
8475472 | Bachman | Jul 2013 | B2 |
20020049402 | Peacock et al. | Apr 2002 | A1 |
20020107530 | Sauer et al. | Aug 2002 | A1 |
20020107531 | Schreck et al. | Aug 2002 | A1 |
20030130571 | Lattouf | Jul 2003 | A1 |
20030167062 | Gambale et al. | Sep 2003 | A1 |
20030167071 | Martin et al. | Sep 2003 | A1 |
20030195524 | Barner | Oct 2003 | A1 |
20030208209 | Gambale et al. | Nov 2003 | A1 |
20040044365 | Bachman | Mar 2004 | A1 |
20040049215 | Snow et al. | Mar 2004 | A1 |
20040068272 | Sauer et al. | Apr 2004 | A1 |
20040181238 | Zarbatany et al. | Sep 2004 | A1 |
20060004410 | Nobis et al. | Jan 2006 | A1 |
20060167338 | Shfaram | Jul 2006 | A1 |
Number | Date | Country |
---|---|---|
19725739 | Apr 1999 | DE |
0570915 | Nov 1993 | EP |
0769272 | Apr 1997 | EP |
0861632 | Sep 1998 | EP |
2 768 324 | Mar 1999 | FR |
09000530 | Jul 1997 | JP |
2003102735 | Apr 2003 | JP |
9308738 | May 1993 | WO |
9515715 | Jun 1995 | WO |
9525468 | Sep 1995 | WO |
9713463 | Apr 1997 | WO |
9727807 | Aug 1997 | WO |
9727893 | Aug 1997 | WO |
9857585 | Dec 1998 | WO |
9900059 | Jan 1999 | WO |
9913777 | Mar 1999 | WO |
99115223 | Apr 1999 | WO |
9935980 | Jul 1999 | WO |
0003759 | Jan 2000 | WO |
0059382 | Oct 2000 | WO |
0060995 | Oct 2000 | WO |
0126557 | Apr 2001 | WO |
0128432 | Apr 2001 | WO |
0166018 | Sep 2001 | WO |
0195809 | Dec 2001 | WO |
0224078 | Mar 2002 | WO |
0234167 | May 2002 | WO |
0245598 | Jun 2002 | WO |
03001893 | Jan 2003 | WO |
03103536 | Dec 2003 | WO |
2005110244 | Nov 2005 | WO |
Number | Date | Country | |
---|---|---|---|
20160192925 A1 | Jul 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13932939 | Jul 2013 | US |
Child | 15067577 | US | |
Parent | 13584476 | Aug 2012 | US |
Child | 13932939 | US | |
Parent | 13027045 | Feb 2011 | US |
Child | 13584476 | US | |
Parent | 11450602 | Jun 2006 | US |
Child | 13027045 | US | |
Parent | 10233879 | Sep 2002 | US |
Child | 11450602 | US |